[go: up one dir, main page]

ATE285415T1 - Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen - Google Patents

Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Info

Publication number
ATE285415T1
ATE285415T1 AT98929035T AT98929035T ATE285415T1 AT E285415 T1 ATE285415 T1 AT E285415T1 AT 98929035 T AT98929035 T AT 98929035T AT 98929035 T AT98929035 T AT 98929035T AT E285415 T1 ATE285415 T1 AT E285415T1
Authority
AT
Austria
Prior art keywords
solid phase
unprotected
aqueous solutions
chemical ligation
native chemical
Prior art date
Application number
AT98929035T
Other languages
English (en)
Inventor
Lynne Canne
Stephen B H Kent
Reyna Simon
Original Assignee
Gryphon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Therapeutics Inc filed Critical Gryphon Therapeutics Inc
Application granted granted Critical
Publication of ATE285415T1 publication Critical patent/ATE285415T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT98929035T 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen ATE285415T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13
PCT/US1998/012278 WO1998056807A1 (en) 1997-06-13 1998-06-12 Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution

Publications (1)

Publication Number Publication Date
ATE285415T1 true ATE285415T1 (de) 2005-01-15

Family

ID=21960431

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98929035T ATE285415T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
AT04029270T ATE354584T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04029270T ATE354584T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Country Status (9)

Country Link
US (4) US6326468B1 (de)
EP (1) EP1001968B1 (de)
JP (1) JP2002505672A (de)
AT (2) ATE285415T1 (de)
AU (1) AU745094B2 (de)
CA (1) CA2292724A1 (de)
DE (2) DE69837170T2 (de)
ES (2) ES2282788T3 (de)
WO (1) WO1998056807A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
ATE285415T1 (de) * 1997-06-13 2005-01-15 Gryphon Therapeutics Inc Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
US6844161B2 (en) * 1997-09-04 2005-01-18 Gryphon Therapeutics, Inc. Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
EP1159289A1 (de) * 1999-03-11 2001-12-05 Gryphon Sciences Chemische synthese und verwendung von löslichen membranproteinrezeptordomänen
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
EP1307214A4 (de) * 2000-08-11 2006-01-18 Invitrogen Corp Hochhomogene molekulare marker für ektrophorese
WO2002018417A1 (en) * 2000-09-01 2002-03-07 Gryphon Therapeutics, Inc. Nucleophile-stable thioester generating compounds, methods of production and use
WO2002057294A2 (en) * 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Zinc finger proteins for dna binding and gene regulation in plants
EP1412517B1 (de) * 2001-03-09 2006-11-29 Boston Probes, Inc. Kombinationsoligomere betreffende verfahren, kits und zusammensetzungen
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
DE60331437D1 (de) * 2002-06-10 2010-04-08 Amylin Pharmaceuticals Inc Nachspaltige sulfurentschützung zur konvergenten proteinherstellung beim verfahren von chemischer ligation
WO2004002469A1 (de) * 2002-06-29 2004-01-08 Aquanova German Solubilisate Technologies (Agt) Gmbh Isoflavonkonzentrate sowie verfahren zu ihrer herstellung
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
AU2003300859A1 (en) * 2002-12-11 2004-06-30 New England Biolabs, Inc. Carrier-ligand fusions and uses thereof
EP1616003A4 (de) 2002-12-30 2007-06-20 Gryphon Therapeutics Inc Wasserlösliche thioester- und selenoesterverbindungen sowie verfahren zur herstellung und verwendung davon
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK1624891T4 (da) * 2003-05-06 2013-07-15 Biogen Idec Hemophilia Inc Kimære koagulationsfaktor Fc proteiner til behandling af hæmofili
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1631597A4 (de) * 2003-05-22 2007-07-11 Gryphon Therapeutics Inc Chemische festphasenligation mit austauschbarem linker
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
CA2555583A1 (en) 2004-02-20 2005-09-09 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
TWI351284B (en) 2004-04-09 2011-11-01 Chugai Pharmaceutical Co Ltd Novel water-soluble prodrugs
EP1749022A2 (de) * 2004-05-24 2007-02-07 Rigel Pharmaceuticals, Inc. Verfahren zur cyclisierung von synthetischen polymeren
US7671023B2 (en) 2005-03-31 2010-03-02 Amylin Pharmaceuticals, Inc. Amylin agonist for treating depression, anxiety disorder and schizophrenia
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US7674881B2 (en) * 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
JPWO2007046456A1 (ja) * 2005-10-19 2009-04-23 中外製薬株式会社 新規水溶性プロドラッグを含有する、膵臓癌、卵巣癌または肝臓癌の予防または治療剤
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
WO2007150053A2 (en) 2006-06-22 2007-12-27 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
EP2120985B1 (de) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 Peptide zur Verwendung bei der Behandlung Psychotischer- und Angsterkrankungen
ES2441197T3 (es) * 2007-08-28 2014-02-03 Ipsen Pharma S.A.S. Método para la síntesis química de polipéptidos y proteínas
EP2536287A4 (de) * 2010-02-18 2015-10-07 Advanced Proteome Therapeutics Inc Ortsspezifische modifikation von proteinen durch chemische modifikation zur bildung von proteinkonjugaten, proteindimerbildung und stapelpeptide
EP2621538B1 (de) 2010-09-28 2015-12-16 Amylin Pharmaceuticals, LLC Manipulierte polypeptide mit verlängerter wirkungsdauer
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
EP2729481B1 (de) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Manipulierte polypeptide mit verbesserter wirkungsdauer und reduzierter immunogenität
FR2981352B1 (fr) 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
EP2850201A4 (de) 2012-05-11 2016-08-31 Alexander Krantz Ortsspezifische markierung und gezielte verabreichung von proteinen zur behandlung von krebs
CA2874436A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
WO2017151939A1 (en) * 2016-03-02 2017-09-08 The Brigham And Women's Hospital, Inc. Use of pla2g5-deficient suppressive macrophages in suppression of inflammation
KR102544146B1 (ko) * 2017-03-02 2023-06-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 아미노산 중합체의 제조방법
EP3861006A1 (de) 2018-10-01 2021-08-11 Université de Genève Verfahren zur herstellung einer vielzahl von polypeptidvarianten zur biologischen analyse
US12103947B2 (en) * 2018-11-30 2024-10-01 Glytech, Inc. Methods for producing peptide thioester and peptide
CA3157359A1 (en) 2019-10-10 2021-04-15 1859, Inc. Methods and systems for microfluidic screening
US20210230218A1 (en) * 2019-10-23 2021-07-29 Mabplex International, Ltd. Oligopeptide linker intermediate and preparation method thereof
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
SI0832096T1 (en) 1995-05-04 2001-12-31 Scripps Research Inst Synthesis of proteins by native chemical ligation
CA2273071C (en) 1996-12-24 2008-07-29 The Scripps Research Institute Method for ligating oligopeptides
ATE285415T1 (de) * 1997-06-13 2005-01-15 Gryphon Therapeutics Inc Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Also Published As

Publication number Publication date
EP1001968A1 (de) 2000-05-24
EP1001968B1 (de) 2004-12-22
US20050209440A1 (en) 2005-09-22
US7030217B2 (en) 2006-04-18
AU8069598A (en) 1998-12-30
ES2282788T3 (es) 2007-10-16
DE69828287D1 (de) 2005-01-27
AU745094B2 (en) 2002-03-14
DE69837170D1 (de) 2007-04-05
WO1998056807A1 (en) 1998-12-17
JP2002505672A (ja) 2002-02-19
ATE354584T1 (de) 2007-03-15
US20020132975A1 (en) 2002-09-19
US7094871B2 (en) 2006-08-22
ES2235336T3 (es) 2005-07-01
US6326468B1 (en) 2001-12-04
DE69837170T2 (de) 2007-11-22
CA2292724A1 (en) 1998-12-17
DE69828287T2 (de) 2005-12-15
US20020169282A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
ATE354584T1 (de) Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
Tsaprailis et al. Influence of secondary structure on the fragmentation of protonated peptides
Dongré et al. Influence of peptide composition, gas-phase basicity, and chemical modification on fragmentation efficiency: evidence for the mobile proton model
Brancia et al. Improved matrix‐assisted laser desorption/ionization mass spectrometric analysis of tryptic hydrolysates of proteins following guanidination of lysine‐containing peptides
NO993341L (no) Analoger av paratyroidhormon
GB2330450B (en) Chemical ionization source for mass spectrometry
NZ527053A (en) Modified amyloid precursor protein polynucleotides and polypeptides
ATE214419T1 (de) Heisshärtende wäschefeste rohbau-versiegelung
WO2003057845A3 (en) Automated systems and methods for analysis of protein post-translational modification
DK0881906T3 (da) Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser
CA2163426A1 (en) Method and apparatus for desorption and ionization of analytes
GB2308227B (en) Electrospray and atmospheric pressure chemical ionization mass spectrometer and ion source
ATE197307T1 (de) Neuroaktive peptide
WO2003074992A3 (en) Phosphorylated proteins and uses related thereto
NO995891L (no) LH-RH peptidanaloger, anvendelser og farmasoeytiske blandinger inneholdende disse
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
WO2004018644A3 (en) HETEROGENEOUS FOLDAMERS CONTAINING α, β, AND/OR Ϝ-AMINO ACIDS
GB9816514D0 (en) Novel method
AUPR378001A0 (en) Protein chip
WO1999020760A3 (en) Herg family potassium ion channel genes and protein
AU2002322506A1 (en) Non-affinity based isotope tagged peptides and methods for using the same
Wang et al. Screening combinatorial libraries for optimal enzyme substrates by mass spectrometry
WO2003087805A8 (en) Method for efficiently computing the mass of modified peptides for mass spectrometry data-based identification
NO982227D0 (no) Urogenitalcarcinom-TPL komplekspeptider og antistoffer derav
EP1518862A3 (de) Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties